U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT06873945) titled 'A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata' on March 07.
Brief Summary: The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata. Alopecia areata is a disease that causes hair loss on the scalp, face, and areas of the body.
Ritlecitinib is approved in many countries at a dose of 50 mg (milligram) taken by mouth once a day for the treatment of patients 12 years and older with severe alopecia areata. This study will look at both the 50 mg dose and a 100 mg dose.
This study is seeking participant...